What is the next treatment for a patient with peripheral neuropathic pain who has failed gabapentin and pregabalin (Lyrica)?

Next Treatment for Neuropathic Pain After Gabapentin and Pregabalin Failure

Duloxetine (60-120 mg daily) is the recommended next-line treatment for patients with neuropathic pain who have failed both gabapentin and pregabalin, offering a Number Needed to Treat of 5.2 and a different mechanism of action through serotonin-norepinephrine reuptake inhibition. 1

Primary Recommendation: Duloxetine

• Start duloxetine at 30-60 mg daily, then increase to 60-120 mg daily as tolerated, which has demonstrated consistent efficacy across neuropathic pain conditions with superior evidence compared to other second-line options 1
• Duloxetine provides pain relief through a completely different mechanism (SNRI) than the failed calcium channel ligands (gabapentin/pregabalin), making it the logical next choice 1
• In patients who failed gabapentin without concomitant antidepressant use, duloxetine showed significantly greater pain reduction than pregabalin at multiple time points, supporting its use even when pregabalin has already failed 2

Alternative Second-Line Options

Tricyclic Antidepressants

• Consider nortriptyline or desipramine (10-25 mg nightly, titrating to 50-150 mg) as alternatives to duloxetine, particularly if cost is a concern, as these have lower anticholinergic side effects than amitriptyline 1
• Obtain an electrocardiogram before initiating tricyclic therapy and avoid in patients with cardiovascular disease due to increased risk of sudden cardiac death at doses >100 mg/day 3
• Tricyclics remain first-line recommendations from the International Association for the Study of Pain consensus panel for neuropathic pain 4

Venlafaxine

• Venlafaxine (50-75 mg daily, increasing to 75-225 mg daily) represents another SNRI option with established efficacy for neuropathic pain 1
• This provides an alternative if duloxetine is not tolerated or contraindicated 1

Topical Therapy for Localized Pain

• Add lidocaine 5% patch for localized neuropathic pain, applied daily to the painful site with minimal systemic absorption, which can be used in combination with systemic medications 1
• Capsaicin 8% patch provides an option for peripheral neuropathic pain with minimal systemic effects and duration of relief lasting at least 12 weeks 1, 5

Critical Dosing Consideration Before Switching

Before abandoning pregabalin, verify the patient received an adequate trial at the maximum recommended dose of 600 mg per day (divided into 2-3 doses), as many patients are undertreated with suboptimal dosing. 1

• The FDA-approved maximum dose in the European Union is 600 mg/day, though the US approval is 300 mg/day; clinical data demonstrate benefit at higher doses in some patients 6
• Implement gradual titration with "asymmetric dosing" (larger dose in evening) to minimize side effects like dizziness and somnolence 7
• An adequate trial requires 3-8 weeks of titration plus 2 weeks at maximum tolerated dose 3

Combination Therapy Strategy

• If single-agent therapy at optimized doses fails, consider combination therapy with medications having different mechanisms of action (e.g., duloxetine plus pregabalin or a tricyclic) 1
• Start with lower doses of each medication when combining to minimize adverse effects 1
• Combination therapy may provide synergistic effects, though evidence supporting this approach is sparse and should be at physician discretion 6

Important Clinical Pitfalls to Avoid

• Do not switch from gabapentin to pregabalin as the next step, as these are both α2-δ calcium channel ligands with similar mechanisms and cross-tolerance is likely 4, 8
• Avoid opioids as second-line therapy; the International Association for the Study of Pain recommends opioids only as second-line treatments after failure of antidepressants and anticonvulsants, with limited evidence for long-term effectiveness 4
• Ensure renal function assessment before any dose adjustments, as both gabapentin and pregabalin require dose reduction in renal impairment (approximately 50% reduction for creatinine clearance 30-60 mL/min) 3

Non-Pharmacological Adjuncts

• Integrate cognitive behavioral therapy, relaxation techniques, and physical therapy to maximize function and provide additional pain relief beyond medications alone 1
• These approaches enhance sense of personal control and should be implemented alongside pharmacotherapy 1

When to Consider Third-Line Options

If duloxetine, tricyclics, and topical agents all fail at optimized doses:

• High-frequency repetitive transcranial magnetic stimulation targeting the motor cortex 9
• Spinal cord stimulation for appropriate candidates 9
• Strong opioids only when no alternative is available, given limited evidence and significant risks 4, 9